Introduction
Angiogenesis is the process by which endothelial cells sprout and migrate from preexisting blood vessels to form new capillaries (1) . Vascular endothelial growth factor (VEGF) is a potent mitogen for endothelial cells and has been shown to be an important growth factor in initiating angiogenesis (2) . Several isoforms of VEGF exist that are formed by alternative splicing. At least six VEGF proteins have been discovered: 121, 145, 165, 183, 189, and 206 (3) . VEGF 165 , VEGF 121 , and VEGF 189 are the most abundantly expressed isoforms.
These isoforms vary in their ability to interact with heparan sulfate proteoglycans (HSPG).
VEGF 121 is the only isoform that is not able to bind to HSPG directly. It lacks exon 7, which encodes for the heparin binding domain (3) . The remaining isoforms vary in their affinity for HSPG. VEGF 189 and VEGF 206 have been found sequestered in the extracellular matrix (ECM) and have a higher affinity for HSPG than VEGF 165 , which is able to interact with HSPG but has not been found to be sequestered in the ECM (4) .
HSPG are expressed in most tissues and are major components of cell surfaces and extracellular matrices (5) . HSPG can participate in physiological processes such as cell adhesion, migration, proliferation, differentiation, and lipoprotein uptake (5) (6) (7) . HSPG consist of a core protein that has generally 1-4 covalently linked heparan sulfate chains consisting of repeating disaccharide units containing N-acetylglucosamine and uronic acid, which can vary in sulfation and epimerizaion (8) . The heparan sulfate (HS) chains can bind various types of ligands such as growth factors and ECM molecules (9) . The negatively charged sulfate groups of HSPG participate in interactions with basic regions of growth factors. HSPG can act as suppressor or activators of growth factor activity. Cell surface HSPG may localize growth factors near their receptors or act as coreceptors for growth factors, while ECM HSPG may act as sites for growth factor storage, sequestering them from cell surface receptors (10) (11) (12) . For example, basic fibroblast growth factor (FGF-2) has been shown to bind to HSPG with high affinity and these interactions potentiate FGF-2 binding to FGF receptors (13) (14) (15) . In addition, it has been shown that VEGF binding to VEGF receptors is dependent on HSPG (16, 17) .
Moreover, VEGF binding to HSPG restores VEGF activity after oxidative damage (18) . It has also been found that low concentrations of heparin potentiate VEGF binding to endothelial cells, while high concentrations of heparin inhibit VEGF binding (16) . HSPG have been identified to be upregulated at active sites of angiogenesis (19, 20) . In addition, the HSPG, glypican-1, has been shown to be expressed in pancreatic cancer cells and the surrounding fibroblasts where it is believed to play a role in tumor growth and progression (21) . Thus, HSPG likely play important roles in regulating VEGF activity during angiogenesis.
Active angiogenesis has been found to play important roles in many pathological and physiological processes, such as tumor progression, diabetic retinopathy, rheumatoid arthritis and wound healing (22) . Environments surrounding tumors and wounds have been shown to be hypoxic in nature (23) . It has been well established that VEGF and its receptors are upregulated in response to hypoxia (24) (25) (26) (27) . Due to the hypoxia, tumor cells undergo high rates of anaerobic glycolysis leading to the production of lactate (28) . These conditions contribute to the acidity of the extracellular environment surrounding tumor cells. In fact, the extracellular space within malignant tissues has been measured to be as low as pH 5.8 (29, 30) . It is possible that the acidic extracellular pH would impact the activity of angiogenic factors within tumors. Indeed, it was found that the rate of VEGF-stimulated microvessel growth is increased at acidic pH (6.9) in an endothelial cell culture model system (31) . Reduced extracellular pH also inhibits apoptotic death in endothelial cells (32) . Thus, local changes in the extracellular environment, such as acidification, might participate in directing angiogenesis to poorly vascularized sites under both normal and pathological conditions. While changes in extracellular pH would certainly impact cell function, there has been little attention focused on the role of pH in regulating angiogenesis or more specifically VEGF activity. Thus, it is possible that decreased local pH could contribute to recruiting new blood vessels to tumors and other poorly vascularized regions. This type of process might involve direct alterations in VEGF interactions and activity in endothelial cells.
To begin to elucidate how local pH changes might affect VEGF, we investigated the impact of pH on VEGF binding and activity in vascular endothelial cells. We found that as pH is decreased, VEGF 165 and VEGF 121 binding to cell surface and extracellular matrix sites increased.
We also found that VEGF 165 and VEGF 121 binding to heparin increased as pH was decreased.
We further found that VEGF stimulation of Erk1/2 was modulated by extracellular pH. Thus, changes in extracellular pH might dramatically impact VEGF mediated angiogenesis.
supplemented with 5% fetal bovine serum and 1% penicillin/streptomycin. NIH-3T3 cells were maintained in low glucose DMEM supplemented with 10% fetal bovine serum, 5 mM glutamine, 0.1 units/mL penicillin G and 0.1 µg/mL streptomycin sulfate. For experiments, BAEC were used at confluence from passages [8] [9] [10] [11] [12] [13] [14] [15] [16] . For experiments, NIH-3T3 cells were used at subconfluence, to prevent cell lifting from the substratum, from passages 4-15 . CHO-K1 cells were used at confluence. Cell number was determined with a Coulter Counter (Miami, FL).
Radiolabeling of VEGF.
125 I-VEGF 165 and 125 I-VEGF 121 were prepared by a modified Bolton-Hunter procedure (33) . Lyophilized VEGF was dissolved in 100 mM sodium phosphate buffer, pH 8. indicating that the radiolabeling procedure did not adversely disrupt VEGF structure.
I-VEGF binding.
Equilibrium binding assays were carried out with confluent cell cultures as previously described (15, 16, 34 
Preparation of ECM-coated dishes.
ECM-coated dishes were prepared as previously described (33, 36, 37) . BAEC were plated at 25,000 cells per well in 24-well dishes. Cells were grown for 3 days and reached confluence. The cells were lysed by incubating the cultures for 3 min at 23°C in a solution containing 0.5% Triton X-100, 20 mM NH 4 OH in phosphate buffered saline, leaving the ECM associated with the culture surface. Subsequently the ECM was washed 4 times with PBS. The ECM remained intact and was characterized to contain HSPG by 35 S labeling of HS chains (data not shown).
Heparin-Sepharose Columns.
Heparin-Sepharose affinity chromatography was used to assess VEGF 165 for 15 min. Columns (1 mL packed with heparin-Sepharose CL-6B) were equilibrated with the column buffers corresponding to those that the growth factor (GF) was incubated in by passing 3 mL of buffer through the columns. Individual columns were prepared for each sample condition.
After the 15 min incubation, the 125 I-GF samples were applied to the columns and the column was washed with the same buffer (1 mL) in which it was equilibrated. Flow through was collected. The 125 I-GF was then eluted with either the same buffer in which it was incubated or the other pH buffer. This eluant was collected and labeled pH Wash. Fractions were TCA precipitated to remove any free 125 I from 125 I-GF. Samples were quantitated in a γ counter. The fraction of 125 I-GF bound to the column was quantified by counting the entire column in a γ counter.
Activation of Erk1/2.
BAEC were plated at 20,000 cells per well in 6-well dishes. After 24 h, the medium was Triton X-100, 150 mM NaCl, 10 mM Tris, pH 7.5, 1 mM EDTA, 1 mM EGTA, 0.5% NP-40 containing 1 mM phenylmethylsulfonyl fluoride and 0.2 mM sodium orthovanadate. Cell lysates were spun at 13,000×g for 10 min at 4°C. Supernatants were collected. BCA protein assays were conducted to determine total protein content. An equal amount of protein from each
Results.
VEGF 165 and VEGF 121 were passed through Sepharose CL-6B columns to ensure that they were interacting with the heparin and not the Sepharose at low pH. It was found that both VEGF 165 and VEGF 121 passed freely through Sepharose CL-6B at pH 7.5 and pH 5.5 (data not shown). Fig. 5 B and D) .
Therefore, heparin and pH may coordinate to regulate VEGF activity.
Erk1/2 activation by VEGF is affected by decreases in extracellular pH.
VEGF stimulates a number of signaling molecules. One that has been well characterized in response to VEGF is activation of the extracellular signal-regulated kinases (Erk1/2) (38).
Since extracellular pH modulates VEGF interactions with BAE cell surfaces, we wanted to determine how these differences might relate to activation of Erk1/2. Quiescent BAEC at various pHs were stimulated with VEGF and the activation of Erk1/2 was analyzed by Western blot (Fig. 6) . At pH 7.5, VEGF 165 stimulated Erk1/2 activation with a peak activation time of 5 min. At pH 6.5, Erk1/2 activation peaked at 10 min. At pH 5.5, Erk1/2 did not appear to be phosphorylated in response to VEGF 165 (Fig. 6A) . Total Erk1/2 was not affected by pH.
VEGF 121 displayed a similar pattern of Erk1/2 activation as that of VEGF 165 (Fig. 6B ). Cell number was determined under each condition and was identical at the three different pHs tested.
Moreover, the Erk1/2 pathway is functional at pH 5. The MAPK pathway has been shown to be activated in response to VEGF in endothelial cells (38) . One component of this pathway is the activation of Erk1/2. In this study, we utilized the activation of Erk1/2 as a marker of biological response to VEGF under different extracellular pHs. It appeared that VEGF-mediated Erk1/2 activation at pH 5.5 was reduced to basal levels.
This data correlates with other results showing that proangiogenic activity is reduced under acidic pH (31, 40) . Moreover, exposing the cells to an acidic pH did not damage cells since cells that were returned to neutral pH could once again be stimulated by VEGF 165 . Also, acidic pH did not appear to induce a permanent change in VEGF structure, in that once VEGF returned to neutral pH, it was able to stimulate Erk1/2 activation.
Our data suggest the possibility that extracellular pH might participate in directing angiogenesis by establishing gradients of VEGF stored within the ECM. In environments where the extracellular pH is decreased, such as at sites of injury and tumors, VEGF may be sequestered in the ECM via its potential new heparin-binding site. As new vasculature is recruited to these sites the pH would increase and the stored VEGF would be released from the ECM to further activate endothelial cells. In conclusion, we have found that extracellular pH can dramatically modulate VEGF binding to and activity in endothelial cells. Increased VEGF deposition within the ECM in hypoxic and locally acidic tissue environments might participate in guiding the growth of new blood vessels to these undervascularized regions. and VEGF 165 at all three pH's evaluated (P < 0.001). 
Figure Legends

